On Wednesday, Pandora Media, Inc. (NYSE:P)’s shares gained 4.80%, and closed at $17.24, as on April 2, the leading internet radio service, declared that its first quarter 2015 financial results will be released on Thursday, April 23, 2015, after the close of the market. The corporation will host a conference call at 2:00 PM (PT) / 5:00 PM (ET) to talk about the quarterly financial results with the investment community.
Pandora Media, Inc. provides Internet radio services in the United States. The corporation allows listeners to create up to 100 personalized stations to access free music and comedy catalogs, in addition to offers Pandora One, a paid subscription service to listeners. It also sells audio, display, and video advertising to advertisers for delivery on computer, mobile, and other connected device.
Medivation, Inc. (NASDAQ:MDVN)’s shares jumped 4.70%, and settled at $132.89, during the last trading session on Wednesday, as on April 2, a biopharmaceutical corporation, and Astellas Pharma Inc. declared topline results from the Phase 2 STRIVE trial comparing enzalutamide with bicalutamide in a study population of men with non-metastatic or metastatic castration-resistant prostate cancer. The study achieved its primary endpoint demonstrating a statistically noteworthyraise in progression-free survival (PFS) for enzalutamide contrast with bicalutamide (Hazard Ratio = 0.24; 95% Confidence Interval, 0.18-0.32; p < 0.0001). Median PFS was 19.4 months in the enzalutamide group contrast with 5.7 months in the bicalutamide group.
The median time on treatment in the STRIVE trial was 14.7 months in the enzalutamide group as compared to 8.4 months in the bicalutamide group. Serious adverse events were stated in 29.4% of enzalutamide-treated patients and 28.3% of bicalutamide-treated patients. Grade 3 or higher cardiac adverse events were stated in 5.1% of enzalutamide-treated patients as compared to 4.0% of bicalutamide-treated patients. One seizure was stated in the trial in the enzalutamide-treated group and none in the bicalutamide-treated group. The most ordinary side effects noted more frequently in the enzalutamide-treated as compared to bicalutamide-treated patients comprised of fatigue, back pain, hot flush, fall, hypertension, dizziness, and reduced appetite, consistent with the known safety profile of enzalutamide.
Medivation, Inc., a biopharmaceutical corporation, focuses on the development and commercialization of novel therapies to treat serious diseases in the United States. It offers XTANDI for the treatment of post-chemotherapy metastatic castration-resistant prostate cancer (mCRPC) patients.
At the end of Wednesday’s trade, Hilton Worldwide Holdings Inc. (NYSE:HLT)’s shares climbed 4.52%, and closed at $30.51, after Hilton Worldwide declared that it will start to eliminate the use of cages for egg-laying chickens and gestation crates for breeding pigs in its global food supply chain. The declaration was made in conjunction with the Humane Society of the United States (HSUS), the nation’s largest animal protection organization.
Initially all hotels in the Hilton Hotels & Resorts, Waldorf Astoria Hotels & Resorts, Conrad Hotels & Resorts, Canopy by Hilton and DoubleTree by Hilton brands will be required to switch all egg usage to cage-free by December 31, 2017, ensuring that chickens are not confined in cages. All pork products must be purchased from suppliers that house breeding pigs in groups rather than gestation crates by December 31, 2018. These changes will initially apply in 19 countries where products are presently accessible and will be adopted in additional markets as supply comes online. These actions are part of the corporation’s global responsible sourcing strategy, which comprises a focus on animal welfare. Last year, Hilton declared a global ban of the sale of shark fin in all owned and managed properties.
Hilton Worldwide Holdings Inc., a hospitality corporation, owns, leases, manages, develops, and franchises hotels, resorts, and timeshare properties worldwide. The corporation operates hotels under 12 brand names, counting Hilton Hotels & Resorts, Waldorf Astoria Hotels & Resorts, Conrad Hotels & Resorts, Canopy by Hilton, Curio - A Collection by Hilton, DoubleTree by Hilton, Embassy Suites Hotels, Hilton Garden Inn, Hampton Hotels, Homewood Suites by Hilton, Home2 Suites by Hilton, and Hilton Grand Vacations.
Halozyme Therapeutics, Inc. (NASDAQ:HALO), ended its Wednesday’s trading session with 4.51% gain, and closed at $15.28, after a biotechnology corporation, declared it plans to proceed with a Phase 3 clinical study (Study 301) of its investigational new drug PEGPH20 in patients with metastatic pancreatic cancer, using a design allowing for potential marketing application based on either progression free survival (PFS) or overall survival.
The use of PFS as the basis for marketing approval will be subject to the overall benefit and risk associated with PEGPH20 combined with nab-paclitaxel (ABRAXANE®) and gemcitabine therapy, counting the:
- Magnitude of the PFS treatment effect observed;
- Toxicity profile; and
- Interim overall survival data.
The study will enroll patients whose tumors accumulate high levels of hyaluronan (HA) – a sugar that is sometimes more prevalent in the areas surrounding cancer cells. Halozyme recently talk abouted the study as part of a planned Type B meeting with the U.S. Food and Drug Administration (FDA).
Halozyme Therapeutics, Inc., a biotechnology corporation, researches, develops, and commercializes human enzymes. Its human enzymes are used to facilitate the delivery of injected drugs and fluids, enhancing the efficacy and the convenience of other drugs or can be used to alter abnormal tissue structures for clinical benefit.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
